Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 10/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631097 | 0.89 | FGFR1 (0.45) | FGFR1SLC22A6EP300 | |
| SCHEMBL13261399 | 0.88 | TLR8 (0.47) | FGFR1EP300 | |
| Methylglyoxal SCHEMBL6013432 | 0.88 | EP300 (0.40) | FGFR1PDE5ASLC22A6EP300MAPT | |
| SCHEMBL4245808 | 0.86 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL25628523 | 0.86 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL13975422 | 0.86 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL27723178 | 0.86 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL27977634 | 0.86 | FGFR1 (0.48) | FGFR1EP300 | |
| SCHEMBL23343373 | 0.85 | FGFR1 (0.44) | FGFR1SLC22A6EP300MAPT | |
| SCHEMBL1892698 | 0.85 | FGFR1 (0.44) | FGFR1SLC22A6EP300MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229036-A9 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240132893-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC LABORATORIES CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4299743-A1 | NUCLEIC ACID MEDICINE EXPRESSING SPLICING VARIANT OF MYOSTATIN | KNC Laboratories Co., Ltd. (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230272403-A1 | ANTISENSE OLIGONUCLEOTIDE INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC LABORATORIES CO., LTD. (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4201484-A1 | ANTISENSE NUCLEIC ACID INDUCING EXON SKIPPING OF ANGIOTENSIN CONVERTING ENZYME 2 GENE | KNC Laboratories Co., Ltd. (JP) | 2023-06-28 | — | — | EP | disclosed |
| EP-3146970-B1 | NUCLEIC ACID DRUG FOR INDUCING SKIPPING OF VARIANT EXON OF CD44 GENE AND INCREASING EXPRESSION OF NORMAL TYPE CD44 MRNA | KNC LABORATORIES CO LTD (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | KNC LABORATORIES CO., LTD. (JP) | 2022-07-14 | — | — | US | disclosed |
| EP-3995153-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | KNC Laboratories Co., Ltd. (JP) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022072645-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-107746852-B | Prostate-associated antigens and vaccine-based immunotherapeutic therapies | 辉瑞公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-1678175-B1 | MEDICAL USE OF ZWITTERIONIC COMPOUNDS BEING CFTR CHANNEL MODULATORS | UNIV JOSEPH FOURIER (FR) | 2008-02-13 | — | — | EP | disclosed |
| EP-1678175-B1 | MEDICAL USE OF ZWITTERIONIC COMPOUNDS BEING CFTR CHANNEL MODULATORS | UNIV JOSEPH FOURIER (FR) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258612-A1 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1678175-A2 | CFTR CHANNEL MODULATORS | Universite Joseph Fourier (FR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005039589-A2 | CFTR CHANNEL MODULATORS | UNIVERSITE JOSEPH FOURIER (FR) | 2005-05-06 | — | — | WO | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| CN-1436082-A | 3 '-or 2' -hydroxymethyl substituted nucleoside derivatives for the treatment of hepatitis virus infections | PHARMASSET LTD (BB) | 2003-08-13 | — | — | CN | disclosed |
| EP-1284741-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | Pharmasset, Ltd. (BB) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001079246-A2 | 3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS | PHARMASSET, LTD. (BB) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258612-A1 | CFTR channel modulators | CFTR, SCNN1B, SCNN1A | FGFR1 3845/4885PDE5A 492/4885SLC22A6 529/4885 |
| US-20220220478-A1 | NUCLEIC ACID DRUG SUPPRESSING PRODUCTION OF MYOSTATIN GENE MRNA | MYOF, MSTN, MTPN | FGFR1 210/4885PDE5A 1754/4885SLC22A6 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.